Genomic Expression Inc., a pioneering biotechnology firm, has successfully raised $1.7 million in a recent funding round to advance its groundbreaking OneRNA™ test. In a world where only 1 out of 4 cancer drugs effectively prolong life, Genomic Expression is on a mission to revolutionize cancer treatment by applying a personalized approach to healthcare. The OneRNA™ test distinguishes itself by sequencing RNA, which enables healthcare professionals to tailor treatment strategies specifically to the genetic makeup of individual tumors. This innovative methodology not only increases the likelihood of therapeutic success but also opens avenues to approved therapies and ongoing clinical trials curated for each patient’s unique genetic profile.
The funding will be pivotal in accelerating the next phases of research, expanding the company’s testing capabilities, and bringing OneRNA™ to the clinician’s toolbox at a faster pace. Furthermore, the capital infusion will support strategic partnerships with leading cancer research institutions to expand the database of RNA-linked therapies and clinical trials, thereby enriching the decision-making process for oncologists. The implications of this funding stretch far beyond the laboratory; they promise a paradigm shift in how we approach cancer treatment, further bridging the gap between cutting-edge genomics and practical medical solutions. With this support, Genomic Expression aims to empower patients and healthcare providers alike to make informed, data-driven decisions that could lead to better outcomes and, ultimately, save lives in the fight against cancer.
